What is BridgeBio Pharma's other accrued liabilities?

BridgeBio Pharma (BBIO) reported other accrued liabilities of $135.51M in Q1 2026.

How has BridgeBio Pharma's other accrued liabilities changed year-over-year?

BridgeBio Pharma's other accrued liabilities increased by 233.2% year-over-year, from $40.67M to $135.51M.

BridgeBio Pharma BBIO Other accrued liabilities

Other accrued liabilities at other companies

PfizerPFE

——

Ionis PharmaceuticalsIONS

——

Roivant SciencesROIV

——

Royalty PharmaRPRX

——

Arrowhead ResearchARWR

——

Neurocrine BiosciencesNBIX

——

Other financials

Income statement

See full

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

See full

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

See full

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation

See full

Market cap$12.98B+119%

Enterprise value$15.36B+178%

P/S22.4×-24.1×

Profitability

See full

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's other accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BridgeBio Pharma's other accrued liabilities?: BridgeBio Pharma (BBIO) reported other accrued liabilities of $135.51M in Q1 2026.
How has BridgeBio Pharma's other accrued liabilities changed year-over-year?: BridgeBio Pharma's other accrued liabilities increased by 233.2% year-over-year, from $40.67M to $135.51M.